From the 1Department of Psychiatry and Behavioural Neurosciences; Department of Obstetrics and Gynecology; Mood Disorders Division; Women's Health Concerns Clinic, McMaster University, Hamilton, Ontario, Canada; and 2Psychiatry and Psychology, Center for Cognitive Medicine, University of Illinois, Chicago, IL.
Received February 8, 2010; revised and accepted February 11, 2010.
Financial disclosure/conflicts of interest: Claudio N. Soares, MD, PhD, FRCPC-Grant/research support: Eli Lilly, AstraZeneca, Physicians Services, Inc. Foundation, Allergen National Centre of Excellence, Hamilton Community Foundation, Wyeth Pharmaceuticals, Canadian Institute of Health Research, National Alliance for Research on Schizophrenia and Depression Foundation. Research consultant: Wyeth, Eli Lilly, Bayer Healthcare Pharmaceuticals, Pfizer. Speakers' bureau: AstraZeneca, Wyeth, Eli Lilly, Pfizer, Lundbeck. Advisory boards: AstraZeneca, Wyeth, Eli Lilly, Bayer Healthcare Pharmaceuticals.
Address correspondence to: Claudio N. Soares, MD, PhD, FRCPC, Women's Health Concerns Clinic, St Joseph's Healthcare Hamilton, 301 James St South, FB 638, Hamilton, Ontario, Canada L8P 3B6. E-mail: [email protected]